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Current normal tissue complication probability (NTCP) models rely 
heavily on dosimetric parameters that are derived from dose-volume 
histograms (DVHs) which lack the spatial information. These 
parameters assume a homogenous response to radiation and tend to 
ignore any inter or intra-organ variation in radiosensitivity. To address 
these issues in our analysis, we developed an image-based approach 
which utilizes the full 3D dose distribution and does not assume any 
prior knowledge of the OARs. Using image registration, we deformed 
CT scans, anatomic structures, and 3D dose distributions from a 
patient cohort onto the same frame of reference “standard patient”. 
Voxel-based correlations between dose and the complication endpoint 
(trismus) were computed over the entire voxel space to construct a 3D 
correlation map. 
We applied this methodology to a cohort of 110 oropharyngeal cancer 
(OPC) patients treated with IMRT and Chemotherapy at MSKCC 
between 2004 and 2009. The results showed a good agreement 
between the image-based approach and the standard NTCP models. 
Both approaches showed a statistically significant correlation between 
the dose to mastication muscles and trismus. Furthermore, the voxel-
wise 3D correlation map provided additional information and revealed 
regions of high correlation outside the mastication muscle region 
which might suggest the involvement of other organs or tissues at risk. 
However, the clinical implication of these new findings needs further 
investigation in an independent data set and might be related to beam 
arrangement and configuration. 
In addition, we also developed a new metric to estimate the 
geometric uncertainty of the underlying deformable registration which 
we denote as distance discordance (DD). More technical details and a 
few examples will be presented to illustrate the concept of DD and its 
impact on the uncertainty of dose mapping. In summary, this study 
demonstrates the validity of this approach and emphasizes the need 
to consider the full 3D dose distribution in conjunction with DVH 
analysis.  
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Many new treatment units are already on the market that operate 
without a flattening filter (FF) or can be operated in a dedicated 
clinical flattening filter free (FFF) mode, i.e. Tomotherapy, 
Cyberknife, Varian’s True-Beam or ELEKTA’s Agility linacs, 
respectively. The commonly accepted dosimetric benefits of FFF high 
energy photon beams, which range from increased dose rate and dose 
per pulse, to favorable output ratio in-air variation with field size, 
reduced energy variation across the beam, reduced leakage and out-
of-field dose, respectively, imply new dosimetric challenges. These 
are related to beam quality specification, beam calibration, small 
field dosimetry, acceptance testing/commissioning, regular quality 
assurance procedures, and finally treatment plan verification.  
As far as the acquisition of basic relative beam parameters is 
concerned, the commissioning of a FFF treatment delivery unit is not 
very different from a standard linac. However, the increased dose 
rate and the high dose per pulse needs to be considered,since some 
point detectors show a pronounced dose rate dependency (e.g. 
diamond detector, liquid filled ionization chamber), possible 
saturation or reduced collection efficiency.  
The forward peaked dose distribution of FFF beams is fundamentally 
different and makes standard parameters as used for quality control 
of linacs, e.g. homogeneity, field flatness and beam penumbra, not 
always viable. Recently suggestions have been made to overcome this 
issue in clinical dosimetry.  
Small field dosimetry is of special importance since all relevant 
clinical applications of FFF beams are closely related to high precision 
radiotherapy techniques, i.e. stereotactic RT or IMRT, where small 
fields/segments build the basis for treatment delivery. 
Today’s challenge of small beam dosimetry and its link to absorbed 
dose determination in reference geometry is enhanced by unflattened 
beams and dedicated high precision radiotherapy delivery units that 
do not allow to setup the reference conditions, as defined by the IAEA 
TRS 398 or AAPM TG 51 codes of practice. Incorrectly measured beam 
output in small beams can result in systematic uncertainties when 
implementing basic beam data in treatment planning systems(TPS), 
misleading results in acceptance testing/ commissioning of a TPS, and 
finally erroneous patient treatments leading to radiation incidents or 
accidents. Therefore correction factors for a variety of commercially 
available small ion chambers and other radiation detectors are 
currently being investigated in order to extend their use towards small 
beam dosimetry in FFF photon beams. 
The accuracy of dose calculation in TPS represents another dosimetric 
aspect. Several studies demonstrated that inverse planning tools for 
IMRT are able to handle unflattened beams and that the dose 
calculation accuracy of commercial TPS is not impaired when 
removing the FF. 
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The advent of the Flattening Filter Free beams (FFF) available on 
common linacs, is facing the community to the ability of treatment 
planning system to accurately model such beams, and with the 
understanding of which are the best sites and treatments which could 
take advantages from using FFF beams. An overview of the published 
data on dose calculation algorithms accuracy for FFF fields is given. 
The characteristics of the FFF beams are here analyzed to evaluate 
the clinical sites where such beams could take advantage. The main 
characteristics relate to the out-of-field dose (peripheral dose) that 
could lower the organs at risk dose; to the high dose rate, allowing 
shorter treatment time for stereotactical treatments; to the profile 
shape that could be better suitable for small targets or simultaneous 
integrated boost treatments.  
A review of published planning studies presents plan comparisons in 
different sites. Prostate, lung, brain, head and neck plans were 
evaluated for IMRT treatment with different beams (6 and 18 MV, 
flattened and unflattened). Also whole breast plans (with different  
techniques from tangents to IMRT) and esophageal treatment 
(conformal, IMRT, VMAT) where analysed by different groups. Results 
of such studies presenting rather large volumes showed no significant 
difference in plan quality between standard flattened and FFF beams. 
A substantial reduction of MUs and consequently of radiation outside 
the target was evidentiated for most of sites, although the opposite 
could be found for very large (or very elongated) targets, where the 
lower off-axis dose would play an unbeneficial role.  
The lower radiation dose outside the target was also studied on 
anthropomorphic phantom to simulate pediatric IMRT treatments with 
FFF beams in the intracranial regions. The measured dose reduction in 
the periphery (from thyroid to ovaries and testes) was lower of 23 to 
70% relative to the standard flattened beams. 
Particular attention is paid to stereotactical treatments, where the 
high dose rate is the clear and natural benefit in treating with FFF 
beams. Studied sites were early stage lung treatments, liver 
metastases and pelvic/abdominal metastases. 
Examples of lung and brain stereotactical comparisons with and 
without flattening filter are given. 
Conclusions: there are benefits in using FFF beams for some 
treatment site and lesion sizes. The primary benefit is, for high dose 
per fraction treatments, the high dose rate that reduces the beam-on 
time. Other proven benefits are the lower out-of-field and peripheral 
dose, that decrease the critical structures dose and the risk of 
secondary cancer induction. 
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Flattening filter free (FFF) options are now commercially available 
and treatments utilising the higher dose-rates obtained are being 
introduced into clinical use. Removal of the flattening filter results in 
an increase, by a factor of 2-6 times, in the instantaneous dose-rate 
of the x-ray pulse compared to the standard flattened beams. The 
increased dose per pulse, result in an equivalent increase in the 
average dose-rate and a potentially similar reduction in overall 
treatment time. The potential radiobiological factors that result from 
changing the instantaneous dose-rate include potential changes to 
sub-lethal damage repair mechanisms, potential synergistic effects 
and the potential radiobiological effects resulting from changes to the 
overall treatment time. A number of in-vitro studies have been 
undertaken using x-ray beams from linear accelerators designed 
specifically to study the implications of changes in dose-rate of the 
treatment beams resulting from treating with flattening filter free 
beams. These studies have used a variety of experimental 
methodologies to achieve the required instantaneous dose-rates and 
differing ways to ensure dose uniformity over the in-vitro flask. These 
differences in the experimental methodologies have not led to 
